RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565

Affiliations

Anna-Maria Wiesinger: Institute of Congenital Metabolic Diseases, Paracelsus Medical University, 5020 Salzburg, Austria
Brian Bigger: European Reference Network for Hereditary Metabolic Diseases, MetabERN, 33100 Udine, Italy
Roberto Giugliani: Department of Genetics, Medical Genetics Service and Biodiscovery Laboratory, Portal Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Casa dos Raros, Porto Alegre 90610-261, Brazil
Christina Lampe: European Reference Network for Hereditary Metabolic Diseases, MetabERN, 33100 Udine, Italy
Maurizio Scarpa: European Reference Network for Hereditary Metabolic Diseases, MetabERN, 33100 Udine, Italy
Tobias Moser: Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria
Christoph Kampmann: Department of Pediatric Cardiology, University Hospital Mainz, 55131 Mainz, Germany
Georg Zimmermann: Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria
Florian B. Lagler: Institute of Congenital Metabolic Diseases, Paracelsus Medical University, 5020 Salzburg, Austria

Abstract

The journal retracts the article, An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis [...]